Genitourinary System Neoplasm

Microarray-based comparative genomic hybridization (aCGH) analysis was carried out on 58 Wilms’ tumor samples. 38 tumors were untreated primary and 20 were recurrent. An increase in copy number change… (full text at CIViC)

PMID 17103382 · Natrajan et al., 2007 · Open in CIViC

77 tumors from Wilms Tumor patients were tested with Illumina BeadChip arrays and genomic profiles were tested for association with relapse and other clinicopathological variables. Copy number gain at… (full text at CIViC)

PMID 22407497 · Perotti et al., 2012 · Open in CIViC

Anaplastic histology (AH) in Wilm's Tumor is characterized by abnormal mitoses, and associated with poor prognosis in comparison to favorable histology (FH). Array CGH was used on 53 AH samples, and a… (full text at CIViC)

PMID 21882282 · Williams et al., 2011 · Open in CIViC

The ABCB1 G2677T/A (S893T, rs2032582) homozygous variant was positively correlated with response to paclitaxel treatment in ovarian cancer patients. 51 epithelial and 2 fallopian tube frozen tumors we… (full text at CIViC)

PMID 16467099 · Gréen et al., 2006 · Open in CIViC

The ABCG2 Q141K variant was correlated with higher progression-free survival and overall survival in 511 ovarian cancer patients treated with platinum + taxane-based chemotherapy.

PMID 22112610 · Tian et al., 2012 · Open in CIViC

High expression of ACTL6A has been shown to be associated with resistance to cisplatin in multiple cancer types. In vitro experiments using A2780cis ovarian cancer cell line showed that overexpression… (full text at CIViC)

PMID 33408251 · Xiao et al., 2021 · Open in CIViC

Phase II trial of AKT-inhibitor capivasertib in patients with solid tumors and AKT1/2/3 alterations. One patient with an AKT1 L52R mutant endometrioid cancer achieved partial response that lasted for … (full text at CIViC)

PMID 35440569 · Shrestha Bhattarai et al., 2022 · Open in CIViC

Phase 2 trial of capivasertib in solid cancer patients with AKT1/2/3 alterations. One patient with metastatic prostate cancer and in-frame AKT2 L78_Q79ins(HANTFVIRCL) that previously progressed on enz… (full text at CIViC)

PMID 35440569 · Shrestha Bhattarai et al., 2022 · Open in CIViC

Analysing 101 samples of metastatic prostate cancer biopsy, a high friequency of structural variants in the AR gene were identified (23/101), comprising a heterogeneous mix of deletion, inversion, tra… (full text at CIViC)

PMID 31932493 · Li et al., 2020 · Open in CIViC

In a clinical study including 168 patients treated with abiraterone or enzalutamide, a multivariate analysis including tumor burden and TP53 status show no significant correlation between AR-V1, AR-V2… (full text at CIViC)

PMID 30209161 · De Laere et al., 2019 · Open in CIViC

Analysis was performed on 224 advanced prostate cancer (PCA) patient samples which had clinical outcome information. Elevated PSA levels in patients after radical prostatectomy are associated with me… (full text at CIViC)

PMID 19244107 · Guo et al., 2009 · Open in CIViC

Using a panel of three androgen-insensitive prostate cancer cell lines (C-81, CWR-R1 and 22Rv1), a novel AR protein isoform was identified. This protein was found to be encoded by three novel alternat… (full text at CIViC)

PMID 19244107 · Guo et al., 2009 · Open in CIViC

Mutations F876L in the ligand binding domain of the androgen receptor confered resistance to enzalutamide and ARN-509, causing these compounds to function as partial agonists in two prostate cancer ce… (full text at CIViC)

PMID 23779130 · Joseph et al., 2013 · Open in CIViC

Ovarian clear cell carcinoma is a relatively chemotherapy-refractory ovarian cancer subtype with a comparatively stable genome and a well-recognized association with endometriosis, but the somatic alt… (full text at CIViC)

PMID 20942669 · Wiegand et al., 2010 · Open in CIViC

Treatment with anti-PD-L1 antibody reduced tumor burden and prolonged survival of mice bearing ARID1A-deficient but not ARID1A-wild-type ovarian tumors. ARID1A deficiency contributes to impaired MMR a… (full text at CIViC)

PMID 29736026 · Shen et al., 2018 · Open in CIViC

This study included 290 patients with Clear Cell Renal Cell Carcinoma whose tumor tissues were sampled and then analyzed. These samples were then divided according to ARID1A expression after immunohis… (full text at CIViC)

PMID 25628030 · Park et al., 2015 · Open in CIViC

In a study of 150 patients with metastatic castration resistant prostate cancer (mCRPC), 71.3% of cases (n=107) harbored androgen receptor (AR) pathway aberrations. Within the AR mutation cohort, 78… (full text at CIViC)

PMID 26000489 · Robinson et al., 2015 · Open in CIViC

In a clinical study including 78 patients with metastatic CRPC, multivariate analyses show that overexpression of AR-V9 is significantly correlated to primary resistance to abiraterone (p = 0.02).

PMID 28473535 · Kohli et al., 2017 · Open in CIViC

In 31enzalutamide-treated and 31 abiraterone-treated patients, detectable levels of AR-V7 was associated with resistance in these patients with castration resistant prostate cancer.

PMID 25184630 · Antonarakis et al., 2014 · Open in CIViC

In a prospective clinical study including 52 patients, expression of AR-FL or AR-V1 or AR-V3 or AR-V7 or AR-V9 are not significantly associated with PSA response change. However, in a multivariate ana… (full text at CIViC)

PMID 31180178 · Sieuwerts et al., 2019 · Open in CIViC

In a clinical study including 54 patients treated with taxane, AR-V567es expression is significantly correlated with a response change in PSA (p = 0.04) and a decrease in PFS (p = 0.02).

PMID 30301829 · Tagawa et al., 2019 · Open in CIViC

Castration Resistant Prostate Cancer (CRPC) often develops after Androgen Deprivation Therapy due to reactivation of transcription of the Androgen Receptor (AR). Transcriptional reactivation can be du… (full text at CIViC)

PMID 28473535 · Kohli et al., 2017 · Open in CIViC

LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion.

PMID 12517791 · Hara et al., 2003 · Open in CIViC

ASNS amplification and expression was associated with resistance to L-asparaginase in ovarian cancer and leukemia cell lines. ASNS silencing increased sensitivity to l-ASP in 2/3 of ovarian cancer cel… (full text at CIViC)

PMID 17088436 · Lorenzi et al., 2006 · Open in CIViC

Argani, et al. (2001) included eight morphologically distinctive renal cell carcinomas with the t(X;17) translocation as seen in alveolar soft part sarcoma (ASPS), with the distinction that the t(X;17… (full text at CIViC)

PMID 28766250 · Ju et al., 2018 · Open in CIViC

Argani, et al. (2001) included eight morphologically distinctive renal cell carcinomas with the t(X;17) translocation as seen in alveolar soft part sarcoma (ASPS), with the distinction that the t(X;17… (full text at CIViC)

PMID 11438465 · Argani et al., 2001 · Open in CIViC

Preclinical evidence for epigenetic inactivation of ASS1 as a determinant of response to platinum chemotherapy suggesting that silencing of ASS1 contributes to treatment failure and clinical relapse i… (full text at CIViC)

PMID 19533750 · Nicholson et al., 2009 · Open in CIViC

This study (PMID 32343890) by de Bono et al, is a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) w… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In a retrospective study, 23 consecutive patients with prostate cancer harboring germline BRCA1/2 or ATM mutations were treated with olaparib were reviewed. This study included 2 patients with BRCA1 m… (full text at CIViC)

PMID 30797618 · Marshall et al., 2019 · Open in CIViC

Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Over… (full text at CIViC)

PMID 26510020 · Mateo et al., 2015 · Open in CIViC

Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Over… (full text at CIViC)

PMID 26510020 · Mateo et al., 2015 · Open in CIViC

A high-throughput screening (HTS) strategy based on synthetic lethality was used to identify drugs that reduce cisplatin resistance in IGROV-CP20 cells, assessed via an MTT colorimetric assay. Various… (full text at CIViC)

PMID 32155756 · Mariniello et al., 2020 · Open in CIViC

To investigate the role of ATP7B in cisplatin resistance, the IGROV-CP20 ovarian cancer cell line was compared to its parental cisplatin-sensitive IGROV line. IGROV-CP20 cells exhibited significantly … (full text at CIViC)

PMID 32155756 · Mariniello et al., 2020 · Open in CIViC